Cancer despite immunosurveillance: Immunoselection and immunosubversion

Nature Reviews Immunology

Volumn 6, Issue 10, 2006, Pages 715-727

  Zitvogel, Laurence ^a   Tesniere, Antoine ^b   Kroemer, Guido ^b  

^a INSERM   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOSPORIN A; GLUCOCORTICOID; IMATINIB; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2;

ANGIOGENESIS; APOPTOSIS; CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER INVASION; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHEDIAK HIGASHI SYNDROME; CORRELATION ANALYSIS; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; INNATE IMMUNITY; METASTASIS; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; TUMOR IMMUNITY;

ANIMALS; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC SURVEILLANCE; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 33748987908     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1936     Document Type: Review

References (127)

1. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000). This landmark review was the first to enumerate systematically the cell-intrinsic characteristics of cancer cells.
2. Dunn, G. P., Old, L. J. & Schreiber, R. D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329-360 (2004). This was the first paper to propose that avoidance of immunosurveillance could be the seventh hallmark of cancer.
3. Smyth, M. J., Dunn, G. P. & Schreiber, R. D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 90, 1-50 (2006).
4. Dunn, G. P., Old, L. J. & Schreiber, R. D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137-148 (2004). This paper brilliantly summarizes the concept of immunoediting.
5. Alfons, B. et al. Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-γ. J. Immunol. 140, 1506-1510 (1988).
6. Takeda, K. et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195, 161-169 (2002). A pioneering study that underscores the role of TRAIL in cancer immunosurveillance.
7. Raulet, D. H. Roles of the NKG2D immunoreceptor and its ligands. Nature Rev. Immunol. 3, 781-790 (2003).
8. Smyth, M. J. et al. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J. Exp. Med. 201, 1973-1985 (2005).
9. Taieb, J. et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nature Med. 12, 214-219 (2006).
10. Dhodapkar, M. V., Krasovsky, J., Osman, K. & Geller, M. D. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J. Exp. Med. 198, 1753-1757 (2003).
11. Beckhove, P. et al. Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J. Clin. Invest. 114, 67-76 (2004).
12. Schmitz-Winnenthal, F. H. et al. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res. 65, 10079-10087 (2005).
13. Willimsky, G. & Blankenstein, T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437, 141-146 (2005). An elegant study showing that immunoediting might not occur for spontaneously arising tumours that overexpress simian virus 40 (SV40).
14. Wang, X. et al. Autoantibody signatures in prostate cancer. N. Engl. J. Med. 353, 1224-1235 (2005).
15. Suzuki, H., Graziano, D. F., McKolanis, J. & Finn, O. J. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin. Cancer Res. 11, 1521-1526 (2005).
16. Li, Y. et al. p53 autoantibodies predict subsequent development of cancer. Int. J. Cancer 114, 157-160 (2005).
17. Egloff, A. M., Weissfeld, J., Land, S. R. & Finn, O. J. Evaluation of anticyclin B1 serum antibody as a diagnostic and prognostic biomarker for lung cancer. Ann. NY Acad. Sci. 1062, 29-40 (2005).
18. Zitvogel, L., Casares, N., Pequignot, M., Albert, M. L. & Kroemer, G. The immune response against dying tumor cells. Adv. Immunol. 84, 131-179 (2004).
19. Pages, F. et al. Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells. Blood 105, 1632-1639 (2005).
20. Nakamura, E. et al. Genetic polymorphisms of the interleukin-4 receptor α gene are associated with an increasing risk and a poor prognosis of sporadic renal cell carcinoma in a Japanese population. Clin. Cancer Res. 8, 2620-2625 (2002).
21. Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med. 10, 942-949 (2004).
22. high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173, 1444-1453 (2004).
23. Reg cells in tumour-induced tolerance.
24. Bronte, V. et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J. Exp. Med. 201, 1257-1268 (2005).
25. Penn, I. Post-transplant malignancy: the role of immunosuppression. Drug Saf. 23, 101-113 (2000).
26. Hollenbeak, C. S. et al. Increased incidence of melanoma in renal transplantation recipients. Cancer 104, 1962-1967 (2005).
27. Kobayashi, N. Malignant neoplasms in registered cases of primary immunodeficiency syndrome. Jpn J. Clin. Oncol. 15 (Suppl. 1), 307-312 (1985).
28. Clementi, R. et al. A proportion of patients with lymphoma may harbor mutations of the perforin gene. Blood 105, 4424-4428 (2005).
29. Sun, T. et al. FASL-844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J. Exp. Med. 202, 967-974 (2005).
30. Carrington, M. et al. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J. Exp. Med. 201, 1069-1075 (2005).
31. Nakachi, K., Hayashi, T., Imai, K. & Kusunoki, Y. Perspectives on cancer immuno-epidemiology. Cancer Sci. 95, 921-929 (2004).
32. Imai, K., Matsuyama, S., Miyake, S., Suga, K. & Nakachi, K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356, 1795-1799 (2000).
33. Hayashi, T. et al. Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance. Cancer Res. 66, 563-570 (2006). References 31-33 introduce the novel concept of two hits for cancer development: first, the oncogenic event that leads to cell-surface expression of stress-associated molecules; and second, the recognition of these molecules by innate immune cells that display receptors with a polymorphism that allows tumour escape.
34. Lowe, S. W., Cepero, E. & Evan, G. Intrinsic tumour suppression. Nature 432, 307-315 (2004).
35. Bartkova, J. et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864-870 (2005).
36. Gorgoulis, V. G. et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434, 907-913 (2005). References 35 and 36 underscore the importance of the oncogene-induced ATM-CHK1-p53 pathway in the control of early pre-malignant lesions as a mechanism of tumour suppression.
37. Gasser, S., Orsulic, S., Brown, E. J. & Raulet, D. H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436, 1186-1190 (2005). This seminal study provided the first indication that the DNA-damage response induced by endogenous stress (in this case, oncogene activation) or therapy is linked to the induction of expression of 'danger' signals.
38. Smyth, M. J. et al. NKG2D function protects the host from tumor initiation. J. Exp. Med. 202, 583-588 (2005).
39. Zhou, H. et al. DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor. Proc. Natl Acad. Sci. USA 102, 10846-10851 (2005).
40. Watson, N. F. et al. Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. Int. J. Cancer 118, 1445-1452 (2006).
41. Holdenrieder, S. et al. Soluble MICA in malignant diseases. Int. J. Cancer 118, 684-687 (2006).
42. Oppenheim, D. E. et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nature Immunol. 6, 928-937 (2005). An elegant study showing the immunosuppressive role of NKG2D ligands on NK-cell functions in mice.
43. Chen, Z. et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730 (2005).
44. Braig, M. et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660-665 (2005).
45. Pardoll, D. M. Spinning molecular immunology into successful immunotherapy. Nature Rev. Immunol. 2, 227-238 (2002).
46. Collado, M. et al. Tumour biology: senescence in premalignant tumours. Nature 436, 642 (2005).
47. Dunn, G. P. et al. A critical function for type I interferons in cancer immunoediting. Nature Immunol. 6, 722-729 (2005).
48. Takaoka, A. et al. Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence. Nature 424, 516-523 (2003).
49. Chaturvedi, V., Bodner, B., Qin, J. Z. & Nickoloff, B. J. Knock down of p53 levels in human keratinocytes increases susceptibility to type I and type II interferon-induced apoptosis mediated by a TRAIL dependent pathway. J. Dermatol. Sci. 41, 31-41 (2006).
50. Stassi, G. et al. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res. 63, 6784-6790 (2003).
51. Wang, T. et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nature Med. 10, 48-54 (2004).
52. Nabarro, S. et al. Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein. J. Exp. Med. 202, 1399-1410 (2005).
53. Kryczek, I. et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203, 871-881 (2006).
54. Pupa, S. M., Tagliabue, E., Menard, S. & Anichini, A. HER-2: a biomarker at the crossroads of breast cancer immunotherapy and molecular medicine. J. Cell. Physiol. 205, 10-18 (2005).
55. Carbone, D. P. et al. Immunization with mutant p53-and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J. Clin. Oncol. 23, 5099-5107 (2005).
56. Muraoka-Cook, R. S., Dumont, N. & Arteaga, C. L. Dual role of transforming growth factor β in mammary tumorigenesis and metastatic progression. Clin. Cancer Res. 11, 937s-943s (2005).
57. Gorelik, L. & Flavell, R. A. Transforming growth factor-β in T-cell biology. Nature Rev. Immunol. 2, 46-53 (2002).
58. + regulatory T cell proliferation. J. Exp. Med. 202, 919-929 (2005).
59. H17 and regulatory T cells. Nature 441, 235-238 (2006).
60. + T cells: eradication of autologous mouse prostate cancer. Cancer Res. 65, 1761-1769 (2005).
61. Green, D. R. & Kroemer, G. The pathophysiology of mitochondrial cell death. Science 305, 626-629 (2004).
62. Debatin, K. M. & Krammer, P. H. Death receptors in chemotherapy and cancer. Oncogene 23, 2950-2966 (2004).
63. Kroemer, G. & Martin, S. J. Caspase-independent cell death. Nature Med. 11, 725-730 (2005).
64. Ravi, R. et al. Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling. Cancer Res. 66, 1730-1739 (2006).
65. Liu, K., Caldwell, S. A. & Abrams, S. I. Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-γ-regulated gene expression. Cancer Res. 65, 4376-4388 (2005).
66. L in cancer patients. J. Immunol. 175, 2709-2714 (2005).
67. Ren, J. et al. MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90. Oncogene 25, 20-31 (2006).
68. low regulatory dendritic cell. J. Immunol. 172, 7341-7349 (2004).
69. H1 type immunity. J. Immunol. 175, 1628-1635 (2005).
70. Dohi, T., Beltrami, E., Wall, N. R., Plescia, J. & Altieri, D. C. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J. Clin. Invest. 114, 1117-1127 (2004).
71. Andersen, M. H., Pedersen, L. O., Becker, J. C. & Straten, P. T. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 61, 869-872 (2001).
72. Asanuma, K., Tsuji, N., Endoh, T., Yagihashi, A. & Watanabe, N. Survivin enhances Fas ligand expression via up-regulation of specificity protein 1-mediated gene transcription in colon cancer cells. J. Immunol. 172, 3922-3929 (2004).
73. Igney, F. H. & Krammer, P. H. Tumor counterattack: fact or fiction? Cancer Immunol. Immunother. 54, 1127-1136 (2005).
74. Wajant, H. CD95L/FasL and TRAIL in tumour surveillance and cancer therapy. Cancer Treat. Res. 130, 141-165 (2006).
75. Bennett, M. W. et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 160, 5669-5675 (1998).
76. Okada, K. et al. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by Fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin. Cancer Res. 6, 3560-3564 (2000).
77. Scott, C. L. et al. Apaf-1 and caspase-9 do not act as tumor suppressors in myc-induced lymphomagenesis or mouse embryo fibroblast transformation. J. Cell Biol. 164, 89-96 (2004).
78. Tanimoto, T. et al. Nuclear expression of cIAP-1, an apoptosis inhibiting protein, predicts lymph node metastasis and poor patient prognosis in head and neck squamous cell carcinomas. Cancer Lett. 224, 141-151 (2005).
79. Tamm, I. et al. XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. Hematol. J. 5, 489-495 (2004).
80. Soengas, M. S. et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409, 207-211 (2001).
81. Umetani, N. et al. Allelic imbalance of APAF-1 locus at 12q23 is related to progression of colorectal carcinoma. Oncogene 23, 8292-8300 (2004).
82. Casares, N. et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202, 1691-1701 (2005). This article provides evidence that the immunogenicity of some chemotherapy protocols is influenced by the propensity of tumour cells to activate caspases.
83. Nikitina, E. Y. et al. Versatile prostate cancer treatment with inducible caspase and interleukin-12. Cancer Res. 65, 4309-4319 (2005).
84. Amarnath, S. M. et al. In vitro quantification of the cytotoxic T lymphocyte response against human telomerase reverse transcriptase in breast cancer. Int. J. Oncol. 25, 211-217 (2004).
85. Maecker, B. et al. Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients. Clin. Exp. Immunol. 141, 558-562 (2005).
86. Ichiki, Y. et al. Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer. J. Immunol. 172, 4844-4850 (2004).
87. Della Porta, M. et al. Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. Oncology 68, 276-284 (2005).
88. Ohm, J. E. et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101, 4878-4886 (2003).
89. Yang, L. & Carbone, D. P. Tumor-host immune interactions and dendritic cell dysfunction. Adv. Cancer Res. 92, 13-27 (2004).
90. Brown, J. R. & DuBois, R. N. COX-2: a molecular target for colorectal cancer prevention. J. Clin. Oncol. 23, 2840-2855 (2005).
91. Stolina, M. et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. 164, 361-370 (2000).
92. Lang, S. et al. Impaired monocyte function in cancer patients: restoration with a cyclooxygenase-2 inhibitor. FASEB J. 17, 286-288 (2003).
93. + T-cell responses through the cell-surface receptor CRTAM. Blood 106, 779-786 (2005).
94. Kroemer, G. & Jaattela, M. Lysosomes and autophagy in cell death control. Nature Rev. Cancer 5, 886-897 (2005).
95. Calderwood, S. K., Theriault, J. R. & Gong, J. Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity. Eur. J. Immunol. 35, 2518-2527 (2005).
96. + T cells. Nature Immunol. 6, 593-599 (2005).
97. Gastpar, R. et al. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res. 65, 5238-5247 (2005).
98. Stefanidakis, M. & Koivunen, E. Cell-surface association between matrix metalloproteinases: role of the complexes in leukocyte migration and cancer progression. Blood 108,1441-1450 (2006).
99. So, T. et al. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res. 65, 5945-5952 (2005).
100. Atkins, D. et al. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int. J. Cancer 109, 265-273 (2004).
101. Medema, J. P. et al. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc. Natl Acad. Sci. USA 98, 11515-11520 (2001).
102. Ochsenbein, A. F. Immunological ignorance of solid tumors. Springer Semin. Immunopathol. 27, 19-35 (2005).
103. Bronte, V. & Zanovello, P. Regulation of immune responses by L-arginine metabolism. Nature Rev. Immunol. 5, 641-654 (2005). A stimulating review about the characterization of myeloid suppressor cells.
104. Uyttenhove, C. et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Med. 9, 1269-1274 (2003).
105. Terness, P. et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196, 447-457 (2002).
106. Huang, Y., Obholzer, N., Fayad, R. & Qiao, L. Turning on/off tumor-specific CTL response during progressive tumor growth. J. Immunol. 175, 3110-3116 (2005).
107. Zhou, G., Lu, Z., McCadden, J. D., Levitsky, H. I. & Marson, A. L. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J. Exp. Med. 200, 1581-1592 (2004).
108. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22, 531-562 (2004).
109. Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Rev. Cancer 5, 263-274 (2005).
110. Terabe, M. & Berzofsky, J. A. Immunoregulatory T cells in tumor immunity. Curr. Opin. Immunol. 16, 157-162 (2004). An overview of the suppressive role of IL-13 produced by NKT cells during tolerance induced by irradiation with ultraviolet light. This suppressive process involves myeloid suppressor cells and TGFβ.
111. Guiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G. & Colombo, M. P. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65, 3437-3446 (2005).
112. + regulatory T cells in human ovarian carcinoma. Cancer Res. 65, 5020-5026 (2005).
113. Coudert, J. D. et al. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood 106, 1711-1717 (2005).
114. + T-cell function during systemic chemotherapy in advanced ovarian cancer. Cancer Res. 65, 7000-7006 (2005).
115. + T cells. J. Exp. Med. 197, 1017-1028 (2003).
116. Faber, P. et al. Frequent genomic alterations in epithelium measured by microsatellite instability following allogeneic hematopoietic cell transplantation in humans. Blood 107, 3389-3396 (2005).
117. Conticello, C. et al. IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J. Immunol. 172, 5467-5477 (2004).
118. Oppenheim, J. J. et al. Autoantigens act as tissue-specific chemoattractants. J. Leukoc. Biol. 77, 854-861 (2005).
119. Bonnotte, B., Crittenden, M., Larmonier, N., Gough, M. & Vile, R. G. MIP-3α transfection into a rodent tumor cell line increases intratumoral dendritic cell infiltration but enhances (facilitates) tumor growth and decreases immunogenicity. J. Immunol. 173, 4929-4935 (2004).
120. Curiel, T. J. et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res. 64, 5535-5538 (2004).
121. Coukos, G., Benencia, F., Buckanovich, R. J. & Conejo-Garcia, J. R. The role of dendritic cell precursors in tumour vasculogenesis. Br. J. Cancer 92, 1182-1187 (2005).
122. + subset. Cancer Res. 47, 3317-3321 (1987).
123. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. (in the press).
124. Borg, C. et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J. Clin. Invest. 114, 379-388 (2004). The first study to show the side-effect of imatinib mesylate on the immune system of mice and patients.
125. Fulda, S. & Debatin, K. M. Targeting apoptosis pathways in cancer therapy. Curr. Cancer Drug Targets 4, 569-576 (2004).
126. Reits, E. A. et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 203, 1259-1271 (2006).
127. Armeanu, S. et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 65, 6321-6329 (2005).